1st stage of Vaccine trails successful for COVID-19:
#GS3#Science and Technology#
- The AZD1222 vaccine is based on a chimpanzee adenovirus and is called ChAdOx1
- The early-stage human trial data of a COVID-19 vaccine developed by AstraZeneca and Oxford University reveals that it is safe and induces an immune response, with mild side effects in some participants.
- The preliminary results of phase I/II trial, published in The Lancet journal, involving 1107 people show that the injection led to them making antibodies and T-cells that can fight coronavirus.
- The study showed 90 percent of involved people developed neutralizing antibodies after one dose. Only ten people were given two doses and all of them produced neutralizing antibodies.
- Oxford’s AZD1222 vaccine is made from a genetically engineered virus that causes the common cold in chimpanzees. However, the virus has been modified so that it doesn’t cause infection in people and also to mimic the coronavirus.
- Scientists did this by transferring the genetic instructions of the coronavirus’ “spike protein” – the crucial tool it uses to invade human cells – to the vaccine. This was done so that the vaccine resembles the coronavirus and the immune system can learn how to attack it.
- The experimental COVID19 vaccine caused minor side effects like fever, chills, and muscle pain more often than in those who got a control meningitis vaccine.